Using Soliris (eculizumab) in combination with the blood cancer treatment obinutuzumab successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) after kidney transplant in a 45-year-old woman, a case study reported for the first time. The woman lost kidney function due to a rare occurrence of aHUS…
Vaccination against COVID-19 was linked to the onset or recurrence of atypical hemolytic uremic syndrome (aHUS) in three Dutch patients in a recent case report. Researchers didn’t find any additional cases wherein a vaccination could be tied to aHUS relapse in a retrospective analysis of 41 other aHUS patients…
Soliris (eculizumab) safely and effectively treated a 46-year-old man with atypical hemolytic uremic syndrome (aHUS) secondary to a scleroderma renal crisis — a life-threatening complication of an autoimmune disorder that can lead to kidney failure. His case was described in the study, “Atypical hemolytic-uremic syndrome due to a scleroderma renal crisis…
The demographics of people hospitalized for hemolytic uremic syndrome (HUS) in the U.S. have shifted over the last decade, with a lower proportion of young children and a higher number of Black patients, a new study reports. “Further surveillance is required to determine if these trends continue,” the researchers wrote.
CellCept (mycophenolate mofetil), an oral immunosuppressant used to prevent organ rejection, was effective in the treatment of a 10-year-old girl with severe atypical hemolytic uremic syndrome (aHUS). Researchers highlighted the importance of early diagnosis and careful monitoring in patient recovery. The study, “Atypical hemolytic uremic syndrome (aHUS)…
Two new mutations in the FHR2 gene were identified for the first time as the cause of severe atypical hemolytic uremic syndrome (aHUS) in a 24-year-old patient. After two years on dialysis, the man underwent a kidney transplant that was preceded by preventive treatment with Soliris (eculizumab) and…
Soliris (eculizumab) can safely be discontinued in children with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission, but close monitoring is necessary due to the possibility of aHUS recurrence, a recent study in the Arabian Gulf region highlights. The study found that more than 70% of…
Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China, AstraZeneca announced. “This milestone reflects our ambition to bring transformative, rare disease medicines to the significant number of patients and families living with rare diseases in China who currently have…
Proteins called factor Ba and sC5b-9 measured in the blood and urine of people with atypical hemolytic uremic syndrome (aHUS) showed they are clinically useful to mark features of the condition, a study showed. Thrombomodulin, a marker of blood vessel damage, and the inflammatory indicator sTNF-RI, combined with factor…
Maintenance treatment with Soliris (eculizumab) every three to six weeks — instead of the standard two weeks — is sufficient to promote complement inhibition and disease remission in most adults with atypical hemolytic uremic syndrome (aHUS), a small study suggests. This extended-dosing regimen is linked to savings of…
Get regular updates to your inbox.